EXHIBIT 99.4

JOINT FILING AGREEMENT

The undersigned hereby agree that the statement on Schedule 13D, dated February 21, 2025 (the “Schedule 13D”), with respect to the common stock, par value $0.0001 of Matinas BioPharma Holdings, Inc. is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an exhibit to the Schedule 13D and each such amendment.

Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning itself contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of February 19, 2025.

	SANITAM PARTNERS LLC

	By:	/s/ Adam Stern
	Name:	Adam Stern
	Title:	Manager

	/s/ Adam Stern
	Adam Stern

	HEZBAY HOLDINGS LLC

	By:	/s/ Ari Kluger
	Name:	Ari Kluger
	Title:	Sole Member

	/s/ Ari Kluger
	Ari Kluger

	PLATINUM POINT CAPITAL, LLC

	By:	/s/ Brian Freifeld
	Name:	Brian Freifeld
	Title:	Manager

	/s/ Brian Freifeld
	Brian Freifeld

Matinas BioPharma Holdings, Inc. SCHEDULE 13D